Levels of Skin-Derived Antileukoproteinase (SKALP)/Elafin in Serum Correlate with Disease Activity During Treatment of Severe Psoriasis with Cyclosporin A
- 1 February 1995
- journal article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 104 (2) , 189-193
- https://doi.org/10.1111/1523-1747.ep12612749
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Epidermis as a Secretory Tissue: An In Vitro Tissue Model to Study Keratinocyte SecretionJournal of Investigative Dermatology, 1994
- Primary structure of the human elafin precursor preproelafin deduced from the nucleotide sequence of its gene and the presence of unique repetitive sequences in the prosegmentBiochemical and Biophysical Research Communications, 1992
- Elafin is a potent inhibitor of proteinase 3Biochemical and Biophysical Research Communications, 1991
- Tissue Plasminogen Activator in PsoriasisJournal of Investigative Dermatology, 1990
- Skin-derived antileucoproteases (SKALPs): characterization of two new elastase inhibitors from psoriatic epidermisBritish Journal of Dermatology, 1990
- Squamous cell carcinoma antigen in patients with cutaneous disordersJournal of the American Academy of Dermatology, 1990
- Tissue Destruction by NeutrophilsNew England Journal of Medicine, 1989
- Enzymatic quantification of polymorphonuclear leucocytes in normal and psoriatic skin following standardized injuryClinical and Experimental Dermatology, 1988
- Elastase-α1-proteinase inhibitor in early diagnosis of neonatal septicemiaThe Journal of Pediatrics, 1986
- Tumor antigen of human cervical squamous cell carcinoma.Correlation of circulating levels with disease progressCancer, 1979